The system is scheduled to be delivered to the institution's newly built cancer center in Yamane, Hidaka-City, by the end of 2022, according to the company. The first patient treatments are expected to begin in early 2023.

The MRIdian system will be used to provide personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers, ViewRay said.